0035630
Bard 5F Infant Cath Kit
$3.00
eaches
In Stock: 49 Eaches
Expiration:
In-Date
Express: Need it tomorrow? Order in next 2 hours 8 minutes and choose overnight shipping at checkout.
Medtronic Biosyn undyed 30" V-20 taper
$165.00 box of 36
Medtronic Biosyn undyed 18" P-12 Reverse Cutting Needle
$8.00 packets
Medtronic Biosyn undyed 30" GS-11 Heavy Body Reverse Cutting
$85.00 box of 36
Medtronic Biosyn undyed 30" CV-23 taper
$89.00 box of 36
Medtronic Maxon green 30" CV-23 taper
$5.25 packets
Medtronic Biosyn undyed 30" GS-21 taper
$94.50 box of 36
Medtronic Monosof black 18" P-16 cutting
$99.00 box of 12
Additional information
| Size | 1 |
|---|---|
| Arms | N/A |
| Manufacturer | |
| Type | Accessories |
| Unit | eaches |
- FDA Product Code: FFH
- FDA Product Code Name: COLLECTOR, URINE, PEDIATRIC, FOR INDWELLING CATHETER
- GMDN Term Code: 65196
- GMDN Term Name: General specimen collection kit
- GMDN Term Description: A collection of devices intended exclusively for professional use for the collection, and preservation and/or transport, of more than one type of clinical specimen (e.g., urine, faeces, sputum, mucous, vaginal secretions) derived from different body regions for laboratory analysis [e.g., nucleic acid technique (NAT), microbiological culture, histopathology]. The kit consists of a specimen sampling/collection tool(s) [e.g., swab, brush, spatula], and a covered receptacle with or without an additive/medium [e.g., preservation solution, microbiological medium (e.g., Amies, Stuart, viral transport/inactivation medium)]. This is a single-use device.
Bard
C.R. Bard (a part of BD - Becton, Dickinson and Company) was a global leader in the development and manufacturing of innovative medical technologies. Known for their high-quality products, Bard specialized in solutions for vascular access, urology, oncology, and surgical specialties. Their product portfolio included catheters, biopsy devices, implantable ports, and hernia repair systems, designed to enhance patient care and procedural efficiency. As part of BD, the legacy of C.R. Bard continues to drive advancements in healthcare, delivering trusted solutions that improve outcomes for patients and providers worldwide.